Skip to main content
Log in

Comparison of initial warfarin response in obese patients versus non-obese patients

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Achieving therapeutic anticoagulation with warfarin is complicated by substantial inter-patient and intra-patient variability with numerous factors known to influence dose requirements. Obesity is one factor for which there remains no study to date investigating its initial effect on warfarin response assessed by INR, stratified by BMI category in hospitalized patients. To compare initial warfarin response between obese and non-obese patients by evaluating average daily dose (ADD), time required to attain therapeutic INR, and mean discharge dose (MDD), stratified by BMI category. A retrospective review was conducted to evaluate initial warfarin response in hospitalized patients of different BMI categories initiated on warfarin with ≥4 consecutive days of therapy and managed by pharmacy dosing service. 211 patients were included (10 underweight, 45 normal weight, 48 overweight, 71 obese, 37 morbidly obese). Across BMI categories, the percentage of patients attaining therapeutic INR prior to discharge differed (p = 0.0004) with 71.1 % of normal weight therapeutic compared to 42.3 % of obese and 38 % of morbidly obese. Within BMI categories, when comparing ADD between patients therapeutic and subtherapeutic at discharge, no differences were observed, except among overweight patients (5.6 ± 0.3 vs. 7 ± 0.4 mg, p = 0.0143). Compared to normal weight, obese and morbidly obese required a significantly longer median time to achieve therapeutic INR (8 and 10 days vs. 6 days) and a higher ADD (6.6 ± 0.3 and 7.6 ± 0.5 vs. 5 ± 0.3 mg) and MDD (6.7 ± 0.5 and 6.7 ± 0.7 vs. 4.4 ± 0.5 mg). Compared to normal weight, obese and morbidly obese patients had a decreased initial response to warfarin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Oake N, Fergusson DA, Forster AJ, van Walraven C (2007) Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 176:1589–1594

    PubMed  Google Scholar 

  2. Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:152S–184S

    Article  Google Scholar 

  3. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM (2005) Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127:2049–2056

    Article  PubMed  CAS  Google Scholar 

  4. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719

    Article  PubMed  CAS  Google Scholar 

  5. Schwarz UI, Ritchie D, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008

    Article  PubMed  CAS  Google Scholar 

  6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87–94

    PubMed  CAS  Google Scholar 

  7. Eichenger S, Hron G, Bialonczyk C et al (2008) Overweight, obesity and the risk of recurrent venous thromboembolism. Arch Intern Med 168(15):1678–1683

    Article  Google Scholar 

  8. Zu Schwabedissen CM, Schmitz VMF, Woodruff S et al (2006) Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol 62:713–720

    Article  Google Scholar 

  9. National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6(Suppl 2):51S–209S

    Google Scholar 

  10. Eccles JT (1975) Control of warfarin therapy in the elderly. Age Ageing 4:161–165

    Article  PubMed  CAS  Google Scholar 

  11. Routledge PA, Chapman PH, Davies DM, Rawlins MD (1979) Factors affecting warfarin requirements. Eur J Clin Pharmacol 15:319–322

    Article  PubMed  CAS  Google Scholar 

  12. Kamali F, Khan TI, King BP et al (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204–212

    Article  PubMed  CAS  Google Scholar 

  13. Ageno W, Steid L, Ultori C et al (2003) The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis. Blood Coagul Fibrinolysis 14:11–14

    Article  PubMed  CAS  Google Scholar 

  14. Gage BF, Eby C, Johnson JA et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326–331

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Financial support for this project was provided in part by the University of Tennessee Health Science Center and Methodist University Hospital.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Timothy H. Self.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wallace, J.L., Reaves, A.B., Tolley, E.A. et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis 36, 96–101 (2013). https://doi.org/10.1007/s11239-012-0811-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0811-x

Keywords

Navigation